Palisade Bio shares are trading higher after the company announced a licensing agreement with Giiant Pharma.
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio has entered into a licensing agreement with Giiant Pharma, causing its shares to trade higher.
September 06, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palisade Bio's stock is trading higher due to a licensing agreement with Giiant Pharma.
The licensing agreement with Giiant Pharma is a positive development for Palisade Bio. This partnership could potentially lead to new revenue streams, hence the increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100